World Journal of Gastrointestinal Oncology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3108)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

156

HTML

1290

Figures (1-2)

267

Tables (1-4)

230

Sum=1943

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

221

Download

545

Sum=766

Publishing Process of This Article

Item

Count

Browse

Download

222

Sum=296

Apr 15, 2024 (publication date) through Mar 31, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(4): 1236-1247 [PMID: 38660650 DOI: 10.4251/wjgo.v16.i4.1236]
URL:	https://www.wjgnet.com/1948-5204/full/v16/i4/1236.htm

Number	Citing Articles
1	Zhengzheng Ji, Ding Fang, Jiasong Li, Ruijie Cao, Handong Wang, Zesong Meng, Zhanjun Guo, Yue Zhao. Serum Alpha-fetoprotein Associated with Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Meta-Analysis and a Retrospective Cohort Study. Hepatitis Monthly 2025; 24(1) doi: 10.5812/hepatmon-145022
2	Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li, Zheng Li. Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(11): 4315-4320 doi: 10.4251/wjgo.v16.i11.4315 Abstract(220) \| Core Tip(210) \| Full Article(HTML)(753) \| Full Article with Cover (PDF)-695K(36) \| Audio-2292K(4) \| Peer-Review Report-219K(22) \| Answering Reviewers-39K(26) \| Full Article (PDF)-369K(44) \| Full Article (XML)-74K(28) \| Times Cited (0) \| Total Visits (1928) \| Open
3	Zhengzheng Ji, Jiasong Li, Shasha Zhang, Yuanyuan Jia, Jing Zhang, Zhanjun Guo. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1480520
4	Yusuf Ilhan, Yakup Ergun. Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategies. World Journal of Gastrointestinal Oncology 2024; 16(7): 2888-2893 doi: 10.4251/wjgo.v16.i7.2888 Abstract(351) \| Core Tip(382) \| Full Article(HTML)(1187) \| Full Article with Cover (PDF)-674K(139) \| Audio-668K(8) \| Peer-Review Report-173K(35) \| Answering Reviewers-97K(29) \| Full Article (PDF)-385K(73) \| Full Article (XML)-90K(41) \| Times Cited (0) \| Total Visits (2787) \| Open
5	Fei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian. Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach. World Journal of Gastrointestinal Oncology 2024; 16(10): 4042-4044 doi: 10.4251/wjgo.v16.i10.4042 Abstract(336) \| Core Tip(276) \| Full Article(HTML)(698) \| Full Article with Cover (PDF)-666K(41) \| Audio-1149K(5) \| Peer-Review Report-170K(26) \| Answering Reviewers-27K(26) \| Full Article (PDF)-336K(45) \| Full Article (XML)-26K(32) \| Times Cited (0) \| Total Visits (1776) \| Open
6	Meer M Chisthi. Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(7): 2884-2887 doi: 10.4251/wjgo.v16.i7.2884 Abstract(357) \| Core Tip(278) \| Full Article(HTML)(877) \| Full Article with Cover (PDF)-639K(49) \| Audio-776K(8) \| Peer-Review Report-216K(31) \| Answering Reviewers-67K(30) \| Full Article (PDF)-344K(64) \| Full Article (XML)-41K(36) \| Times Cited (0) \| Total Visits (2214) \| Open
7	Vishal G Shelat. Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy. World Journal of Gastrointestinal Oncology 2024; 16(10): 4037-4041 doi: 10.4251/wjgo.v16.i10.4037 Abstract(283) \| Core Tip(293) \| Full Article(HTML)(990) \| Full Article with Cover (PDF)-687K(45) \| Audio-3125K(27) \| Peer-Review Report-174K(38) \| Answering Reviewers-51K(37) \| Full Article (PDF)-361K(55) \| Full Article (XML)-54K(39) \| Times Cited (0) \| Total Visits (2447) \| Open
8	Natalia Centrone, Pedro Luiz Serrano Uson Junior. Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?. World Journal of Gastrointestinal Oncology 2024; 16(12): 4753-4756 doi: 10.4251/wjgo.v16.i12.4753 Abstract(204) \| Core Tip(215) \| Full Article(HTML)(556) \| Full Article with Cover (PDF)-664K(32) \| Audio-372K(5) \| Peer-Review Report-203K(29) \| Answering Reviewers-102K(26) \| Full Article (PDF)-344K(47) \| Full Article (XML)-37K(22) \| Times Cited (0) \| Total Visits (1700) \| Open
9	Mao-Ting Zhou, Peng Zhang, Qi Mao, Xiao-Qin Wei, Lin Yang, Xiao-Ming Zhang. Current research status of transarterial therapies for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(9): 3752-3760 doi: 10.4251/wjgo.v16.i9.3752 Abstract(247) \| Core Tip(269) \| Full Article(HTML)(948) \| Full Article with Cover (PDF)-689K(49) \| Audio-1140K(4) \| Peer-Review Report-175K(35) \| Answering Reviewers-155K(34) \| Full Article (PDF)-416K(59) \| Full Article (XML)-209K(33) \| Times Cited (0) \| Total Visits (2398) \| Open

Number	Citing Articles
1	Zhengzheng Ji, Ding Fang, Jiasong Li, Ruijie Cao, Handong Wang, Zesong Meng, Zhanjun Guo, Yue Zhao. Serum Alpha-fetoprotein Associated with Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Meta-Analysis and a Retrospective Cohort Study. Hepatitis Monthly 2025; 24(1) doi: 10.5812/hepatmon-145022
2	Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li, Zheng Li. Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(11): 4315-4320 doi: 10.4251/wjgo.v16.i11.4315 Abstract(220) \| Core Tip(210) \| Full Article(HTML)(753) \| Full Article with Cover (PDF)-695K(36) \| Audio-2292K(4) \| Peer-Review Report-219K(22) \| Answering Reviewers-39K(26) \| Full Article (PDF)-369K(44) \| Full Article (XML)-74K(28) \| Times Cited (0) \| Total Visits (1928) \| Open
3	Zhengzheng Ji, Jiasong Li, Shasha Zhang, Yuanyuan Jia, Jing Zhang, Zhanjun Guo. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1480520
4	Yusuf Ilhan, Yakup Ergun. Maximizing therapeutic outcomes in hepatocellular carcinoma: Insights into combinatorial strategies. World Journal of Gastrointestinal Oncology 2024; 16(7): 2888-2893 doi: 10.4251/wjgo.v16.i7.2888 Abstract(351) \| Core Tip(382) \| Full Article(HTML)(1187) \| Full Article with Cover (PDF)-674K(139) \| Audio-668K(8) \| Peer-Review Report-173K(35) \| Answering Reviewers-97K(29) \| Full Article (PDF)-385K(73) \| Full Article (XML)-90K(41) \| Times Cited (0) \| Total Visits (2787) \| Open
5	Fei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian. Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach. World Journal of Gastrointestinal Oncology 2024; 16(10): 4042-4044 doi: 10.4251/wjgo.v16.i10.4042 Abstract(336) \| Core Tip(276) \| Full Article(HTML)(698) \| Full Article with Cover (PDF)-666K(41) \| Audio-1149K(5) \| Peer-Review Report-170K(26) \| Answering Reviewers-27K(26) \| Full Article (PDF)-336K(45) \| Full Article (XML)-26K(32) \| Times Cited (0) \| Total Visits (1776) \| Open
6	Meer M Chisthi. Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(7): 2884-2887 doi: 10.4251/wjgo.v16.i7.2884 Abstract(357) \| Core Tip(278) \| Full Article(HTML)(877) \| Full Article with Cover (PDF)-639K(49) \| Audio-776K(8) \| Peer-Review Report-216K(31) \| Answering Reviewers-67K(30) \| Full Article (PDF)-344K(64) \| Full Article (XML)-41K(36) \| Times Cited (0) \| Total Visits (2214) \| Open
7	Vishal G Shelat. Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy. World Journal of Gastrointestinal Oncology 2024; 16(10): 4037-4041 doi: 10.4251/wjgo.v16.i10.4037 Abstract(283) \| Core Tip(293) \| Full Article(HTML)(990) \| Full Article with Cover (PDF)-687K(45) \| Audio-3125K(27) \| Peer-Review Report-174K(38) \| Answering Reviewers-51K(37) \| Full Article (PDF)-361K(55) \| Full Article (XML)-54K(39) \| Times Cited (0) \| Total Visits (2447) \| Open
8	Natalia Centrone, Pedro Luiz Serrano Uson Junior. Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?. World Journal of Gastrointestinal Oncology 2024; 16(12): 4753-4756 doi: 10.4251/wjgo.v16.i12.4753 Abstract(204) \| Core Tip(215) \| Full Article(HTML)(556) \| Full Article with Cover (PDF)-664K(32) \| Audio-372K(5) \| Peer-Review Report-203K(29) \| Answering Reviewers-102K(26) \| Full Article (PDF)-344K(47) \| Full Article (XML)-37K(22) \| Times Cited (0) \| Total Visits (1700) \| Open
9	Mao-Ting Zhou, Peng Zhang, Qi Mao, Xiao-Qin Wei, Lin Yang, Xiao-Ming Zhang. Current research status of transarterial therapies for hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(9): 3752-3760 doi: 10.4251/wjgo.v16.i9.3752 Abstract(247) \| Core Tip(269) \| Full Article(HTML)(948) \| Full Article with Cover (PDF)-689K(49) \| Audio-1140K(4) \| Peer-Review Report-175K(35) \| Answering Reviewers-155K(34) \| Full Article (PDF)-416K(59) \| Full Article (XML)-209K(33) \| Times Cited (0) \| Total Visits (2398) \| Open